GTPase HRas

Weijzen S et al. (2002) Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells.

Di Micco R et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication.

Zampino G et al. (2007) Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome.

Zhang X et al. (2006) The HBP1 transcriptional repressor participates in RAS-induced premature senescence.

Sol-Church K et al. (2006) Paternal bias in parental origin of HRAS mutations in Costello syndrome.

Kerr B et al. (2006) Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.

Gripp KW et al. (2006) HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation.

Aoki Y et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome.

Stassou S et al. (2005) A new syndrome of myopathy with muscle spindle excess.

Zutt M et al. (2003) Schimmelpenning-Feuerstein-Mims syndrome with hypophosphatemic rickets.

Zhu JJ et al. (2002) Ras and Rap control AMPA receptor trafficking during synaptic plasticity.

van der Burgt I et al. (2007) Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation.

Oft M et al. (2002) Metastasis is driven by sequential elevation of H-ras and Smad2 levels.

Mochizuki N et al. (2001) Spatio-temporal images of growth-factor-induced activation of Ras and Rap1.

Selcen D et al. (2001) Myopathy with muscle spindle excess: A new congenital neuromuscular syndrome?

Hahn WC et al. (1999) Creation of human tumour cells with defined genetic elements.

Sears R et al. (1999) Ras enhances Myc protein stability.

de Boode WP et al. (1996) Myopathology in patients with a Noonan phenotype.

Russell MW et al. (1996) A 500-kb physical map and contig from the Harvey ras-1 gene to the 11p telomere.

Phelan CM et al. (1996) Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.

Bianchi AB et al. (1993) Reassignment of the H-ras-1 gene to the Hbb-terminus region of mouse chromosome 7.

Piccione M et al. (2009) A premature infant with Costello syndrome due to a rare G13C HRAS mutation.

Sarin KY et al. (2014) Activating HRAS mutation in nevus spilus.

Levinsohn JL et al. (2014) Somatic HRAS p.G12S mutation causes woolly hair and epidermal nevi.

Sarin KY et al. (2013) Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus.

Lorenz S et al. (2013) Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.

Groesser L et al. (2012) Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Hafner C et al. (2011) HRAS mutation mosaicism causing urothelial cancer and epidermal nevus.

Gripp KW et al. (2011) Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C.

Gremer L et al. (2010) Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.

Gough DJ et al. (2009) Mitochondrial STAT3 supports Ras-dependent oncogenic transformation.

Dajee M et al. (2003) NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia.

To MD et al. (2008) Kras regulatory elements and exon 4A determine mutation specificity in lung cancer.

Kuniba H et al. (2009) Prenatal diagnosis of Costello syndrome using 3D ultrasonography amniocentesis confirmation of the rare HRAS mutation G12D.

Lu CW et al. (2008) Ras-MAPK signaling promotes trophectoderm formation from embryonic stem cells and mouse embryos.

McMurray HR et al. (2008) Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype.

Schuhmacher AJ et al. (2008) A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition.

Gripp KW et al. (2008) Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype?

Lo IF et al. (2008) Severe neonatal manifestations of Costello syndrome.

Denayer E et al. (2008) Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation.

Stites EC et al. (2007) Network analysis of oncogenic Ras activation in cancer.

Lim YH et al. (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.

Hiwasa T et al. (1988) Inhibition of cathepsin L-induced degradation of epidermal growth factor receptors by c-Ha-ras gene products.

Stallings RL et al. (1986) Assignment of RAS proto-oncogenes in Chinese hamsters: implications for mammalian gene linkage conservation and neoplasia.

Ishii S et al. (1985) Promoter region of the human Harvey ras proto-oncogene: similarity to the EGF receptor proto-oncogene promoter.

Greenhalgh DA et al. (1985) c-Ha-ras not c-Ki-ras activation in three colon tumour cell lines.

Fujita J et al. (1985) Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors.

Corell B et al. (1988) Comparison between the allelic frequency distribution of the Ha-ras 1 locus in normal individuals and patients with lymphoma, breast, and ovarian cancer.

Tong LA et al. (1989) Structural differences between a ras oncogene protein and the normal protein.

None (1989) ras oncogenes in human cancer: a review.

Ryberg D et al. (1990) Ha-ras-1 alleles in Norwegian lung cancer patients.

Chaganti RS et al. (1985) Germ-line chromosomal localization of genes in chromosome 11p linkage: parathyroid hormone, beta-globin, c-Ha-ras-1, and insulin.

Taparowsky E et al. (1982) Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.

Hafner C et al. (2012) Keratinocytic epidermal nevi are associated with mosaic RAS mutations.

Johnson SM et al. (2005) RAS is regulated by the let-7 microRNA family.

Rocks O et al. (2005) An acylation cycle regulates localization and activity of palmitoylated Ras isoforms.

Vasko V et al. (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors.

Matallanas D et al. (2003) Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization.

Popescu NC et al. (1985) Chromosomal localization of three human ras genes by in situ molecular hybridization.

Nikiforova MN et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Ancrile B et al. (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

Goriely A et al. (2009) Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.

Srivastava SK et al. (1985) Effects of two major activating lesions on the structure and conformation of human ras oncogene products.

Krontiris TG et al. (1993) An association between the risk of cancer and mutations in the HRAS1 minisatellite locus.

Gibbs JB et al. (1984) Autophosphorylation of v-Ha-ras p21 is modulated by amino acid residue 12.

Pincus MR et al. (1983) Prediction of the three-dimensional structure of the transforming region of the EJ/T24 human bladder oncogene product and its normal cellular homologue.

Muschel RJ et al. (1983) The human c-ras1H oncogene: a mutation in normal and neoplastic tissue from the same patient.

Fasano O et al. (1984) Analysis of the transforming potential of the human H-ras gene by random mutagenesis.

Fearon ER et al. (1984) c-Ha-ras-1 oncogene lies between beta-globin and insulin loci on human chromosome 11p.

Jhanwar SC et al. (1983) Localization of c-ras oncogene family on human germ-line chromosomes.

Feinberg AP et al. (1983) Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer.

Capon DJ et al. (1983) Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.

Goyette M et al. (1983) Expression of a cellular oncogene during liver regeneration.

de Martinville B et al. (1983) Oncogene from human EJ bladder carcinoma is located on the short arm of chromosome 11.

Chang EH et al. (1982) Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses.

Der CJ et al. (1982) Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses.

Wong-Staal F et al. (1981) Three distinct genes in human DNA related to the transforming genes of mammalian sarcoma retroviruses.

Fisher JH et al. (1984) Wilms' tumor-aniridia association: segregation of affected chromosome in somatic cell hybrids, identification of cell surface antigen associated with deleted area, and regional mapping of c-Ha-ras-1 oncogene, insulin gene, and beta-globin gene.

Sekiya T et al. (1984) Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient.

Eccles MR et al. (1984) Harvey-ras allele deletion detected by in situ hybridization to Wilms' tumor chromosomes.

Yokota J et al. (1986) Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation.

Colby WW et al. (1986) Biochemical characterization of polypeptides encoded by mutated human Ha-ras1 genes.

NCBI article

OMIM.ORG article

Orphanet article